Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
about
SLC transporters as therapeutic targets: emerging opportunitiesSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.Dapagliflozin: a review of its use in patients with type 2 diabetes.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.SGLT2 Inhibitors: Benefit/Risk Balance.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin.A concise and practical stereoselective synthesis of ipragliflozin L-proline.Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus.Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
P2860
Q27014726-AB9379EE-1C11-442A-B2E6-42DBE994E0B8Q28072765-BD142986-0321-4486-B601-68BC5B30A47BQ30833760-9CE8CEE0-24DF-4984-A212-F30AADAF8BD0Q36277977-1AD51259-37ED-4DDA-9B41-ABE566FC429DQ36926197-DC3C2658-BB27-46D9-B66C-D4EC732D3AADQ37588842-AC400037-20C0-40CD-AEEC-EB9541C93A5BQ37672448-ED0CF634-3BB9-4D40-9134-696673A8554EQ38254252-5D49B64F-59CF-4804-BD38-F871D9736B4EQ38267346-3DB60DFD-83E5-40A8-AA93-E51A5A6C8BE4Q38389823-DE872AA7-C575-413D-8463-F140AB7FD41AQ38515085-63FD1564-4937-4AEF-8B7B-7C4AB8CD71C9Q38524435-F6857095-42C9-4EF4-BD75-8C94E8B60004Q38527885-7C1369A5-1948-46E2-9983-08399DACDF1CQ38619164-92FC011A-900C-4251-A8CF-B85E12F55BEDQ38902321-3764A931-2005-4A51-92EA-92B13CEF5A7AQ38931842-97ACF365-92F1-49CD-B83A-BBC8B92D6562Q39000587-D567C030-5413-4D4D-91E3-ED84864906F3Q39063447-B092664D-2FA3-4871-86E0-8DDC00B4F899Q39300057-10567ADD-0B3C-43CB-98EF-C20692B0A9E2Q41070264-10499906-AC05-414B-9997-0A6FA933BD74Q42382833-96DDC35F-DD42-4BFD-BE0D-6DA0A5A347F4Q51291939-35B29C0B-AF06-4F0F-842E-AB7234203769
P2860
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
@en
type
label
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
@en
prefLabel
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
@en
P2860
P1433
P1476
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
@en
P2860
P2888
P304
P356
10.1007/S40265-014-0225-5
P577
2014-05-01T00:00:00Z
P6179
1006498262